Abstract

Human serum albumin (HSA) is the frontline antioxidant protein in blood with established anti-inflammatory and anticoagulation functions. Here we report that COVID-19-induced oxidative stress inflicts structural damages to HSA and is linked with mortality outcome in critically ill patients. We recruited 39 patients who were followed up for a median of 12.5 days (1-35 days), among them 23 had died. Analyzing blood samples from patients and healthy individuals (n=11), we provide evidence that neutrophils are major sources of oxidative stress in blood and that hydrogen peroxide is highly accumulated in plasmas of non-survivors. We then analyzed electron paramagnetic resonance (EPR) spectra of spin labelled fatty acids (SLFA) bound with HSA in whole blood of control, survivor, and non-survivor subjects (n=10-11). Non-survivor' HSA showed dramatically reduced protein packing order parameter, faster SLFA correlational rotational time, and smaller S/W ratio (strong-binding/weak-binding sites within HSA), all reflecting remarkably fluid protein microenvironments. Following loading/unloading of 16-DSA we show that transport function of HSA maybe impaired in severe patients. Stratified at the means, Kaplan–Meier survival analysis indicated that lower values of S/W ratio and accumulated H2O2 in plasma significantly predicted in-hospital mortality (S/W≤0.15, 81.8% (18/22) vs. S/W>0.15, 18.2% (4/22), p=0.023; plasma [H2O2]>8.6 mM, 65.2% (15/23) vs. 34.8% (8/23), p=0.043). When we combined these two parameters as the ratio ((S/W)/[H2O2]) to derive a risk score, the resultant risk score lower than the mean (< 0.019) predicted mortality with high fidelity (95.5% (21/22) vs. 4.5% (1/22), logrank c2 = 12.1, p=4.9x10-4). The derived parameters may provide a surrogate marker to assess new candidates for COVID-19 treatments targeting HSA replacements and/or oxidative stress.

Data availability

All data generated or analysed during this study are included in the manuscript and supporting files. Raw data collected and used to produce all figures and tables are available on Dyrad (https://doi.org/10.5061/dryad.cnp5hqc4q).

The following data sets were generated

Article and author information

Author details

  1. Mohamed A Badawy

    Research Department, Children's Cancer Hospital Egypt 57357, Cairo, Egypt
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-1691-0167
  2. Basma A Yasseen

    Research Department, Children's Cancer Hospital Egypt 57357, Cairo, Egypt
    Competing interests
    The authors declare that no competing interests exist.
  3. Riem M El-Messiery

    Faculty of Medicine, Cairo University, Cairo, Egypt
    Competing interests
    The authors declare that no competing interests exist.
  4. Engy A Abdel-Rahman

    Research Department, Children's Cancer Hospital Egypt 57357, Cairo, Egypt
    Competing interests
    The authors declare that no competing interests exist.
  5. Aya A Elkhodiry

    Research Department, Children's Cancer Hospital Egypt 57357, Cairo, Egypt
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-5684-0242
  6. Azza G Kamel

    Research Department, Children's Cancer Hospital Egypt 57357, Cairo, Egypt
    Competing interests
    The authors declare that no competing interests exist.
  7. Hajar El-sayed

    Research Department, Children's Cancer Hospital Egypt 57357, Cairo, Egypt
    Competing interests
    The authors declare that no competing interests exist.
  8. Asmaa M Shedra

    Research Department, Children's Cancer Hospital Egypt 57357, Cairo, Egypt
    Competing interests
    The authors declare that no competing interests exist.
  9. Rehab Hamdy

    Research Department, Children's Cancer Hospital Egypt 57357, Cairo, Egypt
    Competing interests
    The authors declare that no competing interests exist.
  10. Mona Zidan

    Research Department, Children's Cancer Hospital Egypt 57357, Cairo, Egypt
    Competing interests
    The authors declare that no competing interests exist.
  11. Diaa Al-Raawi

    Research Department, Children's Cancer Hospital Egypt 57357, Cairo, Egypt
    Competing interests
    The authors declare that no competing interests exist.
  12. Mahmoud Hammad

    Pediatric Oncology Department, Children's Cancer Hospital Egypt 57357, Cairo, Egypt
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-1677-0360
  13. Nahla Elsharkawy

    Clinical pathology department, Children's Cancer Hospital Egypt 57357, Cairo, Egypt
    Competing interests
    The authors declare that no competing interests exist.
  14. Mohamed El Ansary

    Department of Intensive Care, Faculty of Medicine, Cairo University, Cairo, Egypt
    Competing interests
    The authors declare that no competing interests exist.
  15. Ahmed Al-Halfawy

    Department of Pulmonary Medicine, Faculty of Medicine, Cairo University, Cairo, Egypt
    Competing interests
    The authors declare that no competing interests exist.
  16. Alaa Elhadad

    Pediatric Oncology Department, Children's Cancer Hospital Egypt 57357, Cairo, Egypt
    Competing interests
    The authors declare that no competing interests exist.
  17. Ashraf Hatem

    Department of Chest Diseases, Faculty of Medicine, Cairo University, Cairo, Egypt
    Competing interests
    The authors declare that no competing interests exist.
  18. Sherif Abouelnaga

    Pediatric Oncology Department, Children's Cancer Hospital Egypt 57357, Cairo, Egypt
    Competing interests
    The authors declare that no competing interests exist.
  19. Laura L Dugan

    Division of Geriatric Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, United States
    Competing interests
    The authors declare that no competing interests exist.
  20. Sameh Saad Ali

    Research Department, Children's Cancer Hospital Egypt 57357, Cairo, Egypt
    For correspondence
    sameh.ali@57357.org
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-0339-6106

Funding

The Association of Friends of the National Cancer Institute (COVID-SA)

  • Sameh Saad Ali

The Children's Cancer Hospital Egypt (SA-Start up)

  • Sameh Saad Ali

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Human subjects: Written informed consents were obtained from participants in accordance with the principles of the Declaration of Helsinki. For COVID-19 and control blood/plasma collection, Children's Cancer Hospital's Institutional Review Board (IRB) has evaluated the study design and protocol, IRB number 31-2020 issued on July 6, 2020.

Copyright

© 2021, Badawy et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 1,791
    views
  • 206
    downloads
  • 31
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Mohamed A Badawy
  2. Basma A Yasseen
  3. Riem M El-Messiery
  4. Engy A Abdel-Rahman
  5. Aya A Elkhodiry
  6. Azza G Kamel
  7. Hajar El-sayed
  8. Asmaa M Shedra
  9. Rehab Hamdy
  10. Mona Zidan
  11. Diaa Al-Raawi
  12. Mahmoud Hammad
  13. Nahla Elsharkawy
  14. Mohamed El Ansary
  15. Ahmed Al-Halfawy
  16. Alaa Elhadad
  17. Ashraf Hatem
  18. Sherif Abouelnaga
  19. Laura L Dugan
  20. Sameh Saad Ali
(2021)
Neutrophil-mediated oxidative stress and albumin structural damage predict COVID-19-associated mortality
eLife 10:e69417.
https://doi.org/10.7554/eLife.69417

Share this article

https://doi.org/10.7554/eLife.69417

Further reading

    1. Immunology and Inflammation
    Somen K Mistri, Brianna M Hilton ... Jonathan E Boyson
    Research Article

    During thymic development, most γδ T cells acquire innate-like characteristics that are critical for their function in tumor surveillance, infectious disease, and tissue repair. The mechanisms, however, that regulate γδ T cell developmental programming remain unclear. Recently, we demonstrated that the SLAM/SAP signaling pathway regulates the development and function of multiple innate-like γδ T cell subsets. Here, we used a single-cell proteogenomics approach to identify SAP-dependent developmental checkpoints and to define the SAP-dependent γδ TCR repertoire in mice. SAP deficiency resulted in both a significant loss of an immature Gzma+Blk+Etv5+Tox2+ γδT17 precursor population and a significant increase in Cd4+Cd8+Rorc+Ptcra+Rag1+ thymic γδ T cells. SAP-dependent diversion of embryonic day 17 thymic γδ T cell clonotypes into the αβ T cell developmental pathway was associated with a decreased frequency of mature clonotypes in neonatal thymus, and an altered γδ TCR repertoire in the periphery. Finally, we identify TRGV4/TRAV13-4(DV7)-expressing T cells as a novel, SAP-dependent Vγ4 γδT1 subset. Together, the data support a model in which SAP-dependent γδ/αβ T cell lineage commitment regulates γδ T cell developmental programming and shapes the γδ TCR repertoire.

    1. Cancer Biology
    2. Immunology and Inflammation
    Simei Go, Constantinos Demetriou ... Eric O Neill
    Research Article

    The immunosuppressive microenvironment in pancreatic ductal adenocarcinoma (PDAC) prevents tumor control and strategies to restore anti-cancer immunity (i.e. by increasing CD8 T-cell activity) have had limited success. Here, we demonstrate how inducing localized physical damage using ionizing radiation (IR) unmasks the benefit of immunotherapy by increasing tissue-resident natural killer (trNK) cells that support CD8 T activity. Our data confirms that targeting mouse orthotopic PDAC tumors with IR together with CCR5 inhibition and PD1 blockade reduces E-cadherin positive tumor cells by recruiting a hypoactive NKG2D-ve NK population, phenotypically reminiscent of trNK cells, that supports CD8 T-cell involvement. We show an equivalent population in human single-cell RNA sequencing (scRNA-seq) PDAC cohorts that represents immunomodulatory trNK cells that could similarly support CD8 T-cell levels in a cDC1-dependent manner. Importantly, a trNK signature associates with survival in PDAC and other solid malignancies revealing a potential beneficial role for trNK in improving adaptive anti-tumor responses and supporting CCR5 inhibitor (CCR5i)/αPD1 and IR-induced damage as a novel therapeutic approach.